Overview

Vinorelbine for Recurrent ALCL-2017

Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to assess the efficiency and safety of vinorelbine in the treatment of relapsed / advanced ALCL in children and adolescents.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Children's Cancer Group, China
Treatments:
Vinblastine
Vinorelbine
Criteria
Inclusion Criteria:

Children and adolescents with a clear diagnosis of recurrent / progressive ALCL at Shanghai
Children's Medical Center or other centers since September 2017 include:

Diagnosed as ALCL, already received first-line treatment, but get disease progression;
After receiving ALCL treatment has got CR then diagnosed relapse, need for pathological
diagnosis.

Exclusion Criteria:

Patients with other systemic diseases, severe infections or critically illness.